Akebia Announces UK MHRA Approval Of Vafseo For The Treatment Of Symptomatic Anemia Associated With Chronic Kidney Disease In Adults On Chronic Maintenance Dialysis
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics (NASDAQ: AKBA) has received UK MHRA approval for Vafseo, an oral treatment for symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis. The approval is based on data from a comprehensive development program, including the global Phase 3 clinical program of vadadustat.
May 22, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akebia Therapeutics receives UK MHRA approval for Vafseo, a treatment for anemia associated with chronic kidney disease in adults on dialysis.
The UK MHRA approval of Vafseo is a positive development for Akebia Therapeutics, as it expands the company's market reach in Europe. The approval is based on a comprehensive development program, including the global Phase 3 clinical program of vadadustat, which demonstrated non-inferiority to darbepoetin alfa. This is likely to have a positive short-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100